A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

PF-04494700

15 mg for 6 days followed by daily dosing of 5mg

DRUG

PF-04494700

60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.

DRUG

Placebo

Placebo

Trial Locations (62)

10016

Pfizer Investigational Site, New York

10029

Pfizer Investigational Site, New York

10032

Pfizer Investigational Site, New York

14620

Pfizer Investigational Site, Rochester

15213

Pfizer Investigational Site, Pittsburgh

19104

Pfizer Investigational Site, Philadelphia

20007

Pfizer Investigational Site, Washington D.C.

20057

Pfizer Investigational Site, Washington D.C.

20060

Pfizer Investigational Site, Washington D.C.

21224

Pfizer Investigational Site, Baltimore

29425

Pfizer Investigational Site, Charleston

32224

Pfizer Investigational Site, Jacksonville

33140

Pfizer Investigational Site, Miami Beach

33613

Pfizer Investigational Site, Tampa

37208

Pfizer Investigational Site, Nashville

40504

Pfizer Investigational Site, Lexington

40536

Pfizer Investigational Site, Lexington

44122

Pfizer Investigational Site, Beachwood

46202

Pfizer Investigational Site, Indianapolis

48109

Pfizer Investigational Site, Ann Arbor

49503

Pfizer Investigational Site, Grand Rapids

53705

Pfizer Investigational Site, Madison

53792

Pfizer Investigational Site, Madison

60611

Pfizer Investigational Site, Chicago

60612

Pfizer Investigational Site, Chicago

63108

Pfizer Investigational Site, St Louis

75390

Pfizer Investigational Site, Dallas

77030

Pfizer Investigational Site, Houston

77098

Pfizer Investigational Site, Houston

84108

Pfizer Investigational Site, Salt Lake City

85006

Pfizer Investigational Site, Phoenix

85351

Pfizer Investigational Site, Sun City

89106

Pfizer Investigational Site, Las Vegas

90033

Pfizer Investigational Site, Los Angeles

90095

Pfizer Investigational Site, Los Angeles

92037

Pfizer Investigational Site, La Jolla

92081

Pfizer Investigational Site, Vista

92103

Pfizer Investigational Site, San Diego

92128

Pfizer Investigational Site, San Diego

92660

Pfizer Investigational Site, Newport Beach

92697

Pfizer Investigational Site, Irvine

92868

Pfizer Investigational Site, Orange

94117

Pfizer Investigational Site, San Francisco

94121

Pfizer Investigational Site, San Francisco

94143

Pfizer Investigational Site, San Francisco

94304

Pfizer Investigational Site, Palo Alto

94553

Pfizer Investigational Site, Martinez

95817

Pfizer Investigational Site, Sacramento

97201

Pfizer Investigational Site, Portland

98104

Pfizer Investigational Site, Seattle

98108

Pfizer Investigational Site, Seattle

92697-1385

Pfizer Investigational Site, Irvine

92697-3959

Pfizer Investigational Site, Irvine

92697-4285

Pfizer Investigational Site, Irvine

92103-8749

Pfizer Investigational Site, San Diego

06509

Pfizer Investigational Site, New Haven

06510

Pfizer Investigational Site, New Haven

06520

Pfizer Investigational Site, New Haven

30329-5102

Pfizer Investigational Site, Atlanta

02115

Pfizer Investigational Site, Boston

02903

Pfizer Investigational Site, Providence

29406-6076

Pfizer Investigational Site, North Charleston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Alzheimer's Disease Cooperative Study (ADCS)

OTHER

lead

Pfizer

INDUSTRY

NCT00566397 - A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter